Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1000-0.0500 (-2.33%)
At close: 12:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.1500
Open2.1100
Bid2.0000 x 1300
Ask2.1200 x 1100
Day's Range2.1000 - 2.1900
52 Week Range1.5100 - 4.8500
Volume6,932
Avg. Volume814,349
Market Cap50.354M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.2590
Earnings DateNov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EVAX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Evaxion Biotech A/S
    Daily – Vickers Top Buyers & Sellers for 11/09/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    18 days agoArgus Research
View more
  • Benzinga

    Evaxion Biotech Highlights Promising Data From Personalized Cancer Immunotherapy

    Evaxion Biotech A/S (NASDAQ: EVAX) has announced interim safety and immunogenicity data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma. "We are thrilled to announce promising interim data from the first eight patients...All patients demonstrated a specific T-cell immune response induced by the trea

  • GlobeNewswire

    Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

    COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected

  • GlobeNewswire

    Evaxion Announces Third Quarter 2022 Financial Results and Business Update

    Per Norlén, M.D., PhD. joined Evaxion as Chief Executive Officer in October Enrollment of the first patient in our global Phase 2b clinical trial of EVX-01 Increased strategic focus on clinical lead oncology assets and partneringCash and cash equivalents of $17.9 million sufficient to fund operations into mid-2023 COPENHAGEN, Denmark, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company), a clinical-stage biotechnology company specializing in the develo

Advertisement
Advertisement